The improvement in dystrophin was approximately in line with the 5.9% unadjusted improvement seen with Viltepso in a phase 2 study that supported its 2020 approval by the FDA. Shares in Wave rose ...

The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020 accelerated approval.

Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...

The jury also rejected Shinyaku's claim that Sarepta had infringed upon a patent for its DMD drug Viltepso, finding that patent to be invalid, according to Reuters. The FDA granted accelerated ...